Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
BSTC's Cash to Debt is ranked higher than
99% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. BSTC: No Debt )
Ranked among companies with meaningful Cash to Debt only.
BSTC' s Cash to Debt Range Over the Past 10 Years
Min: 0.06  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.98
BSTC's Equity to Asset is ranked higher than
99% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. BSTC: 0.98 )
Ranked among companies with meaningful Equity to Asset only.
BSTC' s Equity to Asset Range Over the Past 10 Years
Min: -5.34  Med: 0.80 Max: 0.98
Current: 0.98
-5.34
0.98
Interest Coverage No Debt
BSTC's Interest Coverage is ranked higher than
99% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BSTC: No Debt )
Ranked among companies with meaningful Interest Coverage only.
BSTC' s Interest Coverage Range Over the Past 10 Years
Min: 80.45  Med: 10000.00 Max: 9999.99
Current: No Debt
80.45
9999.99
F-Score: 6
Z-Score: 191.77
M-Score: -2.04
WACC vs ROIC
17.17%
90.98%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 63.16
BSTC's Operating margin (%) is ranked higher than
97% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. BSTC: 63.16 )
Ranked among companies with meaningful Operating margin (%) only.
BSTC' s Operating margin (%) Range Over the Past 10 Years
Min: -296.7  Med: 4.52 Max: 54.91
Current: 63.16
-296.7
54.91
Net-margin (%) 41.70
BSTC's Net-margin (%) is ranked higher than
95% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. BSTC: 41.70 )
Ranked among companies with meaningful Net-margin (%) only.
BSTC' s Net-margin (%) Range Over the Past 10 Years
Min: -300.13  Med: 29.88 Max: 63.95
Current: 41.7
-300.13
63.95
ROE (%) 26.22
BSTC's ROE (%) is ranked higher than
95% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. BSTC: 26.22 )
Ranked among companies with meaningful ROE (%) only.
BSTC' s ROE (%) Range Over the Past 10 Years
Min: -31.9  Med: 18.06 Max: 61.21
Current: 26.22
-31.9
61.21
ROA (%) 25.55
BSTC's ROA (%) is ranked higher than
98% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. BSTC: 25.55 )
Ranked among companies with meaningful ROA (%) only.
BSTC' s ROA (%) Range Over the Past 10 Years
Min: -156.91  Med: 17.16 Max: 53.14
Current: 25.55
-156.91
53.14
ROC (Joel Greenblatt) (%) 311.38
BSTC's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. BSTC: 311.38 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BSTC' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -406600  Med: 22.82 Max: 275.15
Current: 311.38
-406600
275.15
Revenue Growth (3Y)(%) 6.70
BSTC's Revenue Growth (3Y)(%) is ranked higher than
58% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. BSTC: 6.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BSTC' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -47  Med: 7.15 Max: 65.8
Current: 6.7
-47
65.8
EBITDA Growth (3Y)(%) 10.80
BSTC's EBITDA Growth (3Y)(%) is ranked higher than
67% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. BSTC: 10.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BSTC' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 3.25 Max: 166.8
Current: 10.8
0
166.8
EPS Growth (3Y)(%) -11.60
BSTC's EPS Growth (3Y)(%) is ranked lower than
58% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. BSTC: -11.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BSTC' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -44.1  Med: -0.10 Max: 79.6
Current: -11.6
-44.1
79.6
» BSTC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

BSTC Guru Trades in Q1 2015

Jim Simons 179,200 sh (+23.50%)
Chuck Royce 48,600 sh (unchged)
» More
Q2 2015

BSTC Guru Trades in Q2 2015

Jim Simons 205,489 sh (+14.67%)
Chuck Royce 46,200 sh (-4.94%)
» More
Q3 2015

BSTC Guru Trades in Q3 2015

Chuck Royce 46,200 sh (unchged)
Jim Simons 192,700 sh (-6.22%)
» More
Q4 2015

BSTC Guru Trades in Q4 2015

Jim Simons 253,367 sh (+31.48%)
Chuck Royce 46,200 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with BSTC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 29.29
BSTC's P/E(ttm) is ranked lower than
52% of the 390 Companies
in the Global Biotechnology industry.

( Industry Median: 26.50 vs. BSTC: 29.29 )
Ranked among companies with meaningful P/E(ttm) only.
BSTC' s P/E(ttm) Range Over the Past 10 Years
Min: 14.34  Med: 40.10 Max: 109.97
Current: 29.29
14.34
109.97
Forward P/E 51.02
BSTC's Forward P/E is ranked lower than
89% of the 341 Companies
in the Global Biotechnology industry.

( Industry Median: 16.50 vs. BSTC: 51.02 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 29.29
BSTC's PE(NRI) is ranked higher than
52% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 30.72 vs. BSTC: 29.29 )
Ranked among companies with meaningful PE(NRI) only.
BSTC' s PE(NRI) Range Over the Past 10 Years
Min: 15.05  Med: 43.82 Max: 108.5
Current: 29.29
15.05
108.5
P/B 5.85
BSTC's P/B is ranked lower than
89% of the 1128 Companies
in the Global Biotechnology industry.

( Industry Median: 2.89 vs. BSTC: 5.85 )
Ranked among companies with meaningful P/B only.
BSTC' s P/B Range Over the Past 10 Years
Min: 4.65  Med: 8.52 Max: 500
Current: 5.85
4.65
500
P/S 12.13
BSTC's P/S is ranked lower than
60% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 8.77 vs. BSTC: 12.13 )
Ranked among companies with meaningful P/S only.
BSTC' s P/S Range Over the Past 10 Years
Min: 2.57  Med: 15.79 Max: 75.86
Current: 12.13
2.57
75.86
POCF 30.47
BSTC's POCF is ranked lower than
60% of the 395 Companies
in the Global Biotechnology industry.

( Industry Median: 27.92 vs. BSTC: 30.47 )
Ranked among companies with meaningful POCF only.
BSTC' s POCF Range Over the Past 10 Years
Min: 1.05  Med: 41.53 Max: 3172
Current: 30.47
1.05
3172
EV-to-EBIT 16.04
BSTC's EV-to-EBIT is ranked higher than
57% of the 452 Companies
in the Global Biotechnology industry.

( Industry Median: 18.07 vs. BSTC: 16.04 )
Ranked among companies with meaningful EV-to-EBIT only.
BSTC' s EV-to-EBIT Range Over the Past 10 Years
Min: -128.8  Med: 15.70 Max: 63.9
Current: 16.04
-128.8
63.9
EV-to-EBITDA 15.17
BSTC's EV-to-EBITDA is ranked higher than
50% of the 479 Companies
in the Global Biotechnology industry.

( Industry Median: 15.17 vs. BSTC: 15.17 )
Ranked among companies with meaningful EV-to-EBITDA only.
BSTC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -132.2  Med: 15.50 Max: 62.9
Current: 15.17
-132.2
62.9
Shiller P/E 133.30
BSTC's Shiller P/E is ranked lower than
83% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 47.95 vs. BSTC: 133.30 )
Ranked among companies with meaningful Shiller P/E only.
BSTC' s Shiller P/E Range Over the Past 10 Years
Min: 117.11  Med: 262.10 Max: 1217.5
Current: 133.3
117.11
1217.5
Current Ratio 48.18
BSTC's Current Ratio is ranked higher than
98% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. BSTC: 48.18 )
Ranked among companies with meaningful Current Ratio only.
BSTC' s Current Ratio Range Over the Past 10 Years
Min: 0.43  Med: 5.79 Max: 48.18
Current: 48.18
0.43
48.18
Quick Ratio 48.18
BSTC's Quick Ratio is ranked higher than
98% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. BSTC: 48.18 )
Ranked among companies with meaningful Quick Ratio only.
BSTC' s Quick Ratio Range Over the Past 10 Years
Min: 0.41  Med: 5.09 Max: 48.18
Current: 48.18
0.41
48.18
Days Sales Outstanding 72.21
BSTC's Days Sales Outstanding is ranked lower than
54% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. BSTC: 72.21 )
Ranked among companies with meaningful Days Sales Outstanding only.
BSTC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 5.36  Med: 114.97 Max: 299.91
Current: 72.21
5.36
299.91

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.20
BSTC's Price/Net Cash is ranked lower than
60% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: 5.54 vs. BSTC: 8.20 )
Ranked among companies with meaningful Price/Net Cash only.
BSTC' s Price/Net Cash Range Over the Past 10 Years
Min: 2.85  Med: 12.18 Max: 65.22
Current: 8.2
2.85
65.22
Price/Net Current Asset Value 6.73
BSTC's Price/Net Current Asset Value is ranked lower than
57% of the 893 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. BSTC: 6.73 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BSTC' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.05  Med: 7.65 Max: 40.52
Current: 6.73
1.05
40.52
Price/Tangible Book 5.90
BSTC's Price/Tangible Book is ranked lower than
64% of the 1047 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. BSTC: 5.90 )
Ranked among companies with meaningful Price/Tangible Book only.
BSTC' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.59  Med: 3.30 Max: 475
Current: 5.9
0.59
475
Price/Projected FCF 7.75
BSTC's Price/Projected FCF is ranked lower than
78% of the 283 Companies
in the Global Biotechnology industry.

( Industry Median: 2.87 vs. BSTC: 7.75 )
Ranked among companies with meaningful Price/Projected FCF only.
BSTC' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.66  Med: 9.57 Max: 133
Current: 7.75
0.66
133
Price/Median PS Value 0.77
BSTC's Price/Median PS Value is ranked higher than
56% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 1.24 vs. BSTC: 0.77 )
Ranked among companies with meaningful Price/Median PS Value only.
BSTC' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.04  Med: 0.52 Max: 4.3
Current: 0.77
0.04
4.3
Price/Graham Number 2.77
BSTC's Price/Graham Number is ranked lower than
57% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 3.04 vs. BSTC: 2.77 )
Ranked among companies with meaningful Price/Graham Number only.
BSTC' s Price/Graham Number Range Over the Past 10 Years
Min: 0.39  Med: 2.40 Max: 12.36
Current: 2.77
0.39
12.36
Earnings Yield (Greenblatt) (%) 6.23
BSTC's Earnings Yield (Greenblatt) (%) is ranked higher than
87% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. BSTC: 6.23 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BSTC' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.6  Med: 3.80 Max: 1356.6
Current: 6.23
1.6
1356.6

More Statistics

Revenue(Mil) $21
EPS $ 1.22
Beta2.04
Short Percentage of Float8.84%
52-Week Range $30.70 - 72.07
Shares Outstanding(Mil)6.92

Business Description

Industry: Biotechnology » Biotechnology
Compare:NONOF, AMGN, GILD, BIIB, CELG » details
BioSpecifics Technologies Corp was incorporated in Delaware in 1990. It is a biopharmaceutical company engaged in the development of an injectable collagenase for multiple indications. The Company has a development and license agreement with Auxilium Pharmaceuticals, Inc. for injectable collagenase for indications in development. Auxilium is currently selling XIAFLEX in the U.S. for the treatment of Dupuytren's contracture and Peyronie's disease. In December 2013, FDA approved Auxilium's supplemental Biologics License Application ('sBLA') for XIAFLEX for the treatment of Peyronie's disease. The Company and its licensees face competition from larger pharmaceutical companies, specialty pharmaceutical companies and biotechnology firms, universities and other research institutions and government agencies that are developing and commercializing pharmaceutical products. As a biopharmaceutical company, the Company is subject to a large body of legal and regulatory requirements.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK